<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443065</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 17 / ACCORD 20/0904</org_study_id>
    <secondary_id>2009-012797-12</secondary_id>
    <nct_id>NCT01443065</nct_id>
  </id_info>
  <brief_title>MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma</brief_title>
  <acronym>MEGA</acronym>
  <official_title>MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentre, open-label, randomized phase II trial is ongoing in 30 centres in France.
      Main eligibility criteria include: histologically proven adenocarcinoma of the stomach,
      esophagus or gastroesophageal junction; locally advanced or metastatic disease; measurable
      disease (RECIST 1.1); no known HER2 overexpression; no prior palliative chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomised to modified FOLFOX6 (oxaliplatin 85 mg/m2, FA 400 mg/m², FU 400 mg/m²
      bolus then 2400 mg/m² over 46 hr) alone or combined to either panitumumab (6 mg/kg) or AMG
      102 (10 mg/kg), every two weeks until unacceptable toxicity or disease progression. Judgment
      criteria include 4-month progression-free survival (PFS) rate (primary endpoint), OS,
      objective response rate, and safety. Ancillary studies aim to identify candidate predictive
      and prognostic biomarkers among functional of molecular alterations of the EGFR/RAS/RAF and
      HGF/c-Met pathways, and to monitor circulating tumour cells and circulating immune cells
      (myeloid derived suppressor cells, NK cells) in sequential blood samples taken at baseline
      and through the study treatment. A total of 165 pts will be enrolled (Fleming's one-step
      design)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 4 months</measure>
    <time_frame>4 months</time_frame>
    <description>based on the proportion of success in each patient group (patient without progression at 4 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>until progression or death</time_frame>
    <description>Progression-free survival is defined as the time from randomization to progression (RECIST v1.1 criteria) or death. Patients alive without progression will be censored at the last tumoral evaluation and 5 years maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>until death</time_frame>
    <description>Overall survival is defined as the time from randomization to death any cause or last follow-up news (censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>4 months</time_frame>
    <description>Time to progression is defined as the time from randomization to progression (RECIST v1.1 criteria). Patients alive without progression will be censored at the last tumoral evaluation. Patients died without progression will be censored at the death date any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate (OR) (= complete responses [CR] + partial responses [PR]) according to RECIST V1.1</measure>
    <time_frame>until progression</time_frame>
    <description>The objective tumor response will be evaluated by the investigator with RECIST v1.1 criteria every 8 (± 1) weeks up to disease progression. Patients with symptoms suggestive of disease progression will have a tumoral evaluation when symptoms will occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response duration</measure>
    <time_frame>until progression</time_frame>
    <description>The Objective response duration is defined as time from first Complete Response or Partial Response to progression. Patients died without progression will be censored at death date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (Complete Response + Partial Response + stable disease [SD])</measure>
    <time_frame>4 months</time_frame>
    <description>The tumor control rate is rate of objective responses (complete responses and partial responses) and stable disease responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of the treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Tolerability of the treatment will be based on toxicities of evaluated products by clinical and biological measurements (NCIC/CTC (CTCAE V4) criteria, except for peripheral neuropathy toxicity (Lévi scale)).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Malignant Neoplasm of Esophagus</condition>
  <condition>Malignant Neoplasm of Stomach</condition>
  <arm_group>
    <arm_group_label>Arm A : simplified Folfox 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every 2 weeks :
Oxaliplatin : 85 mg/m2 over 120 mn (2h) IV on D1
Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 followed by :
5-fluoro-uracil : 400 mg/m² in IV bolus on D1 followed by :
5-fluoro-uracil : 2400 mg/m² in IV infusion over 46 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : simplified FOLFOX 4 + panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 2 weeks :
Oxaliplatin : 85 mg/m2 over 120 mn IV on D1
Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y to oxaliplatin) followed by :
5-fluoro-uracil : 400 mg/m², IV bolus on D1, followed by :
5-fluoro-uracil : 2400 mg/m², IV infusion IV over 46 h
Panitumumab : 6 mg/kg de 60 à 90 mn ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the 1st infusion of panitumumab is well tolerated, the next infusions can be administered over 30 ± 10 mn.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C : simplified FOLFOX 4 + AMG 102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 2 weeks :
Oxaliplatin : 85 mg/m2 over 120 mn IV on D1
Folinic Acid : 400 mg/m² (racemic) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y/concomitant with oxaliplatin) followed by :
5-fluoro-uracil : 400 mg/m² IV bolus on D1 followed by :
5-fluoro-uracil : 2400 mg/m² in IV perfusion over 46 h
AMG 102 : 10 mg/kg over 60 ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the first infusion is well tolerated (without severe infusion-related reactions), the following infusions can be administered over 30 ± 10 mn.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85mg/m² over 120 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A : simplified Folfox 4</arm_group_label>
    <arm_group_label>Arm B : simplified FOLFOX 4 + panitumumab</arm_group_label>
    <arm_group_label>Arm C : simplified FOLFOX 4 + AMG 102</arm_group_label>
    <other_name>Eloxatine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>400mg/m² over 120 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A : simplified Folfox 4</arm_group_label>
    <arm_group_label>Arm B : simplified FOLFOX 4 + panitumumab</arm_group_label>
    <arm_group_label>Arm C : simplified FOLFOX 4 + AMG 102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluoro-uracil</intervention_name>
    <description>400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A : simplified Folfox 4</arm_group_label>
    <arm_group_label>Arm B : simplified FOLFOX 4 + panitumumab</arm_group_label>
    <arm_group_label>Arm C : simplified FOLFOX 4 + AMG 102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panitumumab</intervention_name>
    <description>6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm B : simplified FOLFOX 4 + panitumumab</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG102</intervention_name>
    <description>10mg/kg over 60 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm C : simplified FOLFOX 4 + AMG 102</arm_group_label>
    <other_name>Rilotumumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the stomach, the esophagus or the cardia (with
             or without signet ring cells; intestinal, diffuse or mixed form).

          -  Locally advanced (non resectable) or metastatic disease.

          -  Measurable disease (at least one measurable tumor) according to the RECIST V1.1
             criteria (the tumor should not be located in a previous field of radiation).

          -  Absence of previous palliative chemotherapy. Previous neo-adjuvant or adjuvant
             chemotherapies (alone or combinated with radiotherapy) are authorized, including
             biotherapy (except anti-EGFR or anti-c-Met / HGF), if it has been stopped at least 12
             months before inclusion.

          -  Previous radiotherapy authorized if stopped at least 14 days before randomization and
             if at least one measurable target outside the radiation area is present.

          -  No major surgery ≤ 28 days, or minor surgery ≤ 14 days, prior to randomization

          -  Sites of disease evaluated within 28 days prior to randomization with
             thoracic-abdominal-pelvic CT scan (or abdominal-pelvic MRI plus Chest X-ray).

          -  Age ≥ 18 years.

          -  Patient general status : ECOG 0-1.

          -  Life expectancy ≥ 3 months.

          -  Hemoglobin &gt; or = 9 g/L - (transfusion authorized if necessary), PNN ≥ 1,5.109/l,
             platelets ≥ 100.109/l.

          -  Hepatic transaminases ≤ 2.5 times upper limit of normal (ULN) (≤ 5 ULN in case of
             hepatic metastases), alkaline phosphatase ≤ 2.5 ULN (≤ 5 ULN in case of hepatic
             metastases), total bilirubinemia ≤ 1.5 ULN)

          -  Creatinine clearance (calculated or measured) ≥ 50 ml / min, serum creatinine &gt; 1.5
             ULN

          -  Prothrombin time (PT) ≥ 60 %, INR &lt; 1,5 (except if anticoagulant therapy)

          -  Magnesemia and calcemia ≥ Lower Limit of Normal (LLN)

          -  Negative Pregnancy test for women of child-bearing age.

          -  Information given to the patient and signed informed consent.

          -  Public Health insurance coverage.

          -  Sample of tumour (primitive or metastatic) available.

        Exclusion Criteria:

          -  Known brain or leptomeningeal metastases.

          -  Positive HER2 Status (IHC 3+ or IHC2+/FISH or CISH+) .

          -  contraindication, allergy or hypersensitivity to ANY OF the study treatments.

          -  Prior Treatment with EGFR inhibitor or HGF / c-Met inhibitor.

          -  Patient already included in another clinical trial testing an experimental drug.

          -  Peripheral edema &gt; grade 2.

          -  Proteinuria &gt; 1 g/24h

          -  Clinically significant cardiovascular disease (such as unstable angina pectoris,
             severe congestive heart failure, uncontrolled severe cardiac arrhythmia) within 12
             months prior to randomization.

          -  Thrombosis or ischemic vascular event during the last 12 months (deep venous
             thrombosis, pulmonary embolism, STROKE or established cerebral infarction, myocardial
             infarction).

          -  Medical history or signs of interstitial pneumopathy or pulmonary fibrosis.

          -  Peripheral neuropathy &gt; grade 1.

          -  Clinically significant hemorrhage of the upper gastrointestinal tract (requiring blood
             transfusion or hemostatic interventional procedure.

          -  Actively evolutive inflammatory bowel disease or any other intestinal disease causing
             chronic diarrhea (≥ grade 2).

          -  Any uncontrolled concomitant disease (e.g., uncontrolled diabetes) or medical history
             (e.g., organ transplantation) which, according to the opinion of the investigator, may
             interfere with the interpretation of the study results.

          -  Any comorbidity or situation which, according to the opinion of the investigator,
             could increase the risk of toxicity (e.g., Dihydropyrimidine dehydrogenase
             deficiency).

          -  Chronic or active HIV, HBV or HCV infections.

          -  Severe and\or not healed wound.

          -  Any active infection requiring systemic treatment, or any uncontrolled infection
             within 14 days before randomization.

          -  Other concomitant malignancy or history of cancer (except carcinoma in situ of the
             cervix, or non melanoma skin cancer, with curative intent treatment), except when
             considered in complete remission for at least 5 years before randomization.

          -  Pregnant women or women who might become pregnant during the study (or who plan to
             become pregnant within 6 months after the last administration of a study drug) or
             lactating women.

          -  Men or women who have the age of procreation and who do not abide with the use of a
             highly efficient contraceptive means (according to the current institutional
             standards) or, alternatively, the use of abstinence during the study treatment and
             until 6 months after last administration of the study drugs.

          -  Patient unwilling to comply with the medical follow-up required by the trial because
             of geographic social or psychological reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David MALKA, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric FRANCOIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne-NICE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno BUECHER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe BORG, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Andre Boulloche-MONTBELIARD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuelle SAMALIN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Val d'Aurelle Paul Lamarque-MONTPELLIER</affiliation>
  </overall_official>
  <overall_official>
    <last_name>You Heng LAM, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Paul Papin-ANGERS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François GHIRINGHELLI, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges Francois Leclerc-DIJON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Driffa MOUSSATA, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud-PIERRE BENITE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Pierre GALAIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Francois Baclesse-CAEN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédérique CVITKOVIC, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre René Huguenin-SAINT-CLOUD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Claire KAMINSKY, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Alexis Vautrin-VANDOEUVRE LES NANCY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier BOUCHE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Robert Debré - REIMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien TAIEB, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou-PARIS (HEGP)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cédric LECAILLE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique Bordeaux Nord Aquitaine-BORDEAUX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves BECOUARN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié-BORDEAUX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara DAUVOIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier La Source-ORLEANS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien FORESTIER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Edouard Herriot-LYON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaafar BENNOUNA, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre René Gauducheau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christelle DE LA FOUCHARDIERE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe BORG, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Jean Minjoz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Baptiste BACHET, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier La Pitié Salpétrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Luc RAOUL, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leila BENGRINE LEFEVRE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Antoine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent MIGLIANICO, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHP Saint Grégoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laetitia DAHAN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier La Timone</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas APARICIO, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Avicenne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé PERRIER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Joseph</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Philippe METGES, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Morvan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric TERREBONNE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpîtal haut Lévèque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal ARTRU, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Privé Jean Mermoz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaël DEPLANQUE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Saint Joseph</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel MAILLARD, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Annecy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine ADENIS, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Locally advanced (non operable) or metastatic</keyword>
  <keyword>First line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

